The device, called a nomogram, works by measuring the levels of PSA in the patient’s blood. Researchers at Fox Chase recently found that they could accurately predict a patient’s risk of dying from prostate cancer by measuring the time between the last radiation treatment and biochemical failure.
Nomograms currently exist to help patients and physicians decide on a course of treatment, but this is the first kind to determine a patient’s death risk after receiving treatment.
Related Articles on Medical Devices:
GE’s New MRI Machine Gets FDA Approval
FDA Approves Gel to Temporarily Stop Blood Flow
FDA Clears Siemens’ Mobilett Mira Mobile Digital X-Ray System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
